Cargando…
Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology
This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lympho...
| Clasificación: | Libro Electrónico |
|---|---|
| Autores principales: | , |
| Autor Corporativo: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Cham :
Springer International Publishing : Imprint: Springer,
2016.
|
| Edición: | 1st ed. 2016. |
| Colección: | SpringerBriefs in Immunology,
|
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-319-46906-5 | ||
| 003 | DE-He213 | ||
| 005 | 20220121015017.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 160923s2016 sz | s |||| 0|eng d | ||
| 020 | |a 9783319469065 |9 978-3-319-46906-5 | ||
| 024 | 7 | |a 10.1007/978-3-319-46906-5 |2 doi | |
| 050 | 4 | |a QR180-189.5 | |
| 072 | 7 | |a MJCM |2 bicssc | |
| 072 | 7 | |a MED044000 |2 bisacsh | |
| 072 | 7 | |a MJCM |2 thema | |
| 082 | 0 | 4 | |a 571.96 |2 23 |
| 082 | 0 | 4 | |a 616.079 |2 23 |
| 100 | 1 | |a Lasek, Witold. |e author. |4 aut |4 http://id.loc.gov/vocabulary/relators/aut | |
| 245 | 1 | 0 | |a Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology |h [electronic resource] / |c by Witold Lasek, Radoslaw Zagozdzon. |
| 250 | |a 1st ed. 2016. | ||
| 264 | 1 | |a Cham : |b Springer International Publishing : |b Imprint: Springer, |c 2016. | |
| 300 | |a VII, 75 p. 6 illus. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a SpringerBriefs in Immunology, |x 2194-2781 | |
| 520 | |a This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies). | ||
| 650 | 0 | |a Immunology. | |
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Cytokines. | |
| 650 | 0 | |a Oncology. | |
| 650 | 0 | |a Cytology. | |
| 650 | 1 | 4 | |a Immunology. |
| 650 | 2 | 4 | |a Cancer Biology. |
| 650 | 2 | 4 | |a Cytokines and Growth Factors. |
| 650 | 2 | 4 | |a Oncology. |
| 650 | 2 | 4 | |a Cell Biology. |
| 700 | 1 | |a Zagozdzon, Radoslaw. |e author. |4 aut |4 http://id.loc.gov/vocabulary/relators/aut | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783319469058 |
| 776 | 0 | 8 | |i Printed edition: |z 9783319469072 |
| 830 | 0 | |a SpringerBriefs in Immunology, |x 2194-2781 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-3-319-46906-5 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||